Search Results - "Shembalkar, Jayashree"

Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations by Sahay, Rakesh K., Giri, Richa, Shembalkar, Jayashree V., Gupta, Sandeep K., Mohan, Brij, Kurmi, Prakash, Kumar, S. Ravindra, Sawardekar, Vinayak M., Mishra, Ashutosh, Murthy, L. Sreenivasa, Arya, Vivek V., Sonawane, Abhijit R., Soni, Pravin N., Gofne, Sandip K., Karnawat, Shital R., Rajurkar, Mandodari N., Patel, Piyush M., Lakhwani, Lalit K., Mehta, Suyog C., Joglekar, Sadhna J.

“…Introduction This study compared efficacy and safety of triple drug fixed-dose combination (FDC) of dapagliflozin (DAPA) + sitagliptin (SITA) + metformin (MET)…”
Get full text

A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial by Singh, Awadhesh Kumar, Sahay, Rakesh, Gil, Navneet, Tripathi, Sudhir, Khandelwal, Vipul, Basu, Indraneel, Shembalkar, Jayashree, Srivastava, Manoj Kumar, Bhatia, Girish, Pathak, Vaishali, Dange, Amol, Chaudhri, Mayura, Naskar, Arindam, Mondal, Ashish, Gangwal, Pawan, Kumar, Surendra, Kumar, Deepak, Raju, Yandrapati gnana sundara, Sorate, Sanket, Gavli, Onkar, Kumbalkar, Sunita, Varade, Deepak, Chaudhari, Harshal, Prasad, Durga, Patil, Manoj, Bhagwat, Nikhil, Agarwal, Rohit, Pandey, Arun, Ghosh, Soumya, Patil, Shubhashree, Kini, Vishal, Sharma, Akhilesh, Mayabhate, Mayur, Pawar, Roshan, Rajput, Aashish, Shahavi, Vinakaya

“…Objective To assess the efficacy and safety of fixed-dose combinations (FDC) of triple-drug dapagliflozin, sitagliptin, and metformin (DSM) compared with FDC…”
Get full text

Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study by Ajmani, Ajay Kumar, Agrawal, Aparna, Prasad, B.L.N., Basu, Indraneel, Shembalkar, Jayashree, Manikanth, Neeraj, Subrahmanyam, K.A.V., Srinivasa, M., Chawla, Manoj, Srivastava, Manoj Kumar, Jebasingh, Felix, Achappa, Basavaprabhu, Agrawal, R.P., Pulichikkat, Rakesh K., Meena, Ramdhan, Bhatia, Shailaja, Gupta, Sandeep Kumar, Dange, Amol, Srivastava, Ambrish, Trailokya, Abhijit, Shahavi, Vinayaka, Shende, Sachin

“…This study aimed to assess efficacy and safety of evogliptin versus sitagliptin, when added to background metformin therapy in Indian patients with…”
Get full text